3Rs Beyond Boundaries: The 3Rs Across Disciplines

coming soon

Arianna Giusti is Senior Scientific Manager at Cosmetics Europe, where she leads collaborative efforts with external research platforms and organisations, oversees multidisciplinary projects, and focuses on the development and regulatory acceptance of New Approach Methodologies. Her work also covers policy and regulatory aspects related to animal testing. In this context, she co-chairs the Cosmetics Advocacy Priority Team within the International Collaboration for Cosmetics Safety (ICCS) supporting global alignment and acceptance of non-animal methods, and represents Cosmetics Europe in the European Partnership for Alternatives to Animal Testing and in the ECHA Collaborative Platform on Alternatives to Animal Testing. She previously served as Scientific Consultant for ICCS, where she contributed to aligning scientific capabilities, regulatory acceptance, and education programmes with a particular focus on NAMs.

She holds a PhD in Toxicology from the University of Leuven in Belgium, obtained within the Marie Curie Initial Training Network project MarPipe under the Horizon 2020 programme. She previously completed a master’s degree in Molecular Biology and Genetics at the University of Pavia and a bachelor’s degree in Medical Biotechnology at the University of Florence in Italy.

Dominic Hildebrand is Head of Quality Control for Biotherapeutics at Bayer in Wuppertal, Germany. He joined Bayer in 2013, starting his career in research before moving into quality control for clinical products in 2017. Trained as a biochemist, he earned his PhD in Molecular Medicine through research conducted in Tübingen and Boston. Today, he is actively involved in the development and quality oversight of innovative cell- and gene-based therapies, helping to translate scientific advances into new treatment options for patients.

Safety pharmacologist with >15 years of experience in nonclinical safety and translational risk assessment across small molecules and emerging modalities. Expertise in CNS and cardiovascular safety pharmacology, with a strong focus on the development and implementation of human‑relevant in vitro models (including hiPSC‑based neuronal and cardiac systems) and NAMs.

Dr Kris Meurrens graduated in 1989 as veterinarian at the University of Ghent.

Almost immediately after his veterinary studies he got involved in the management of laboratory animal facilities, meaning that he has more than 30 years experience.

Between 1992 and 2000 he was director of Laboratory Animal Center of University of Leuven (KU Leuven). In 2000 he completed the Master in Laboratory Animal Science at Ghent University.

From 2000 to 2011 he worked as Eurotox-registered toxicologist and veterinarian in an AAALAC-accredited in vivo toxicology contract research facility.

After the closure of that facility he worked shortly in the animal facilities of the Vrije Universiteit Brussels and GSK Biologicals.

In 2012 he returned to KU Leuven as director of Laboratory Animal Center.

He is also the vice-president and treasurer in the Board of the Belgian Council for Laboratory Science, vice-president of the Vlaamse Proefdierencommissie (former Deontological Committee, i.e. advisory committee of the Minister for animal experimentation matters), member of the Steering committee of Re-Place and IC3R-centre VUB and of other lab animal science organisations.

Dr Mark Post, MD/PhD, has had several academic appointments at Utrecht University, Harvard University, Dartmouth college, Eindhoven University of Technology and Maastricht University. He currently is professor of Sustainable Industrial Tissue Engineering at Maastricht University. He is visiting professor at Harvard, University of Modena and faculty at Singularity University. His main research interest is the engineering of tissues for various applications. Tissue engineering for Food has led to the development of cultured beef from bovine skeletal muscle stem cells. The same technology is used to culture leather. Dr Post co-authored more than 200 papers in leading peer-reviewed scientific journals and coordinated several national consortia with funding and awards from different sources including government, charity and industry. He is a frequent speaker at international events on innovation in the agrifood sector. He presented the world’s first hamburger from cultured beef in the August 2013 for which he received the World Technology Award from AAAS/Times/Forbes. Dr Post is CSO and co-founder of Mosa Meat and of Qorium, two companies that aim to commercialize meat and leather applications of tissue engineering. Together, these companies have 120 employees, including 50 scientists.